eClinical Technology and Industy News

Fore Biotherapeutics Announces First Patient Dosed in Global Phase 2 Trial Evaluating FORE8394 in BRAF-Mutated Solid and Brain Tumors

Excerpt from the Press Release:

PHILADELPHIA–(BUSINESS WIRE)–Fore Biotherapeutics (Fore Bio), a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients, today announced that the first patient has been dosed in the global Phase 2 FORTE clinical trial evaluating FORE8394 with cobicistat in patients with solid or central nervous system (CNS) tumors with BRAF gene fusions and recurrent primary CNS tumors with BRAFV600E mutations refractory to standard therapies. The FORTE master protocol trial builds upon the design and interim data of the ongoing Phase 1/2a clinical trial evaluating FORE8394 in advanced solid and CNS tumors with BRAF alterations.

“We are thrilled to have initiated our global Phase 2 trial of FORE8394 in patients with BRAF-mutated tumors who have previously received available treatments and are now in need of alternative therapies,” said Stacie Shepherd, MD, PhD., Chief Medical Officer of Fore Biotherapeutics. “FORE8394, our next-generation BRAF paradox breaker, provides the potential for single agent clinical activity for both BRAF V600mutations and BRAF fusions without MAPK pathway activation, avoiding the resistance and toxicities observed with the earlier-generation BRAF inhibitors. Advancing this novel therapy to address patients’ needs is the driving force behind our team’s mission to advance FORE8394 through the clinic. The dosing of the first patient is a significant milestone for the entire FORE team. With the FDA’s Fast Track Designation of FORE8394 in the third quarter of this past year, we look forward to continuing to develop FORE8394, working with the FDA and other global regulatory agencies to address the high unmet need for patients suffering from these difficult to treat cancers.”

The FORTE trial is a global, multi-center, single-arm, open-label, Phase 2 master protocol evaluating the safety and efficacy of FORE8394 with cobicistat, a pharmacokinetic booster commonly used with HIV medications, in patients 10 years of age and older with cancer harboring BRAF alterations.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?